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A B S T R A C T
Background: The ‘Two Week Wait’ policy aims to ensure patients with suspected cancer are seen within two
weeks of referral. However, patient non-attendance can result in this target being missed. This study aimed to
identify predictors of non-attendance; and analyse the relationship between attendance and outcomes including
cancer diagnosis and early mortality.
Methods: A cohort study of 109,433 adults registered at 105 general practices, referred to a cancer centre within
a large NHS hospital trust (April 2009 to December 2016) on the ‘Two Week Wait’ pathway.
Results: 5673 (5.2%) patients did not attend. Non-attendance was largely predicted by patient factors (younger
and older age, male gender, greater deprivation, suspected cancer site, earlier year of referral, greater distance to
the hospital) over practice factors (greater deprivation, lower Quality and Outcomes Framework score, lower
cancer conversion rate, lower cancer detection rate). 10,360 (9.6%) patients were diagnosed with cancer within
six months of referral (9.8% attending patients, 5.6% non-attending patients). Among these patients, 2029
(19.6%) died within 12 months of diagnosis: early mortality risk was 31.3% in non-attenders and 19.2% in
attending patients.
Conclusions: Non-attendance at urgent referral appointments for suspected cancer involves a minority of patients
but happens in predictable groups. Cancer diagnosis was less likely in non-attending patients but these patients
had worse early mortality outcomes than attending patients. The study findings have implications for cancer
services and policy.
1. Background
Short term cancer mortality rates are consistently higher in the UK
than other comparable countries [1,2] in part due to rates of late stage
diagnosis and emergency presentation [3–5]. The Two Week Wait
(2WW) policy was introduced for all cancers in 2000 to address waiting
list concerns. All NHS patients in England and Wales with suspected
cancer should be seen within two weeks of general practitioner (GP)
referral [2]. The policy was also expected to reduce geographical
variation in referral patterns and waiting times, and reduce social in-
equalities in cancer diagnosis and outcomes [2]. as both later stage
presentation and shorter survival times are associated with increased
deprivation [3,6–8].
Earlier diagnosis of cancer is a priority in many developed coun-
tries, and in the UK [9] the relevant NICE guidance to GPs was last
updated in 2015 [10]. Two Week Wait is a high volume referral
pathway in England and Wales, now more than 1.9 million referrals
annually [11], and an estimated 48.7% of cancers included in the policy
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are identified through this route [12]. Referral results in a cancer di-
agnosis in 8.3% of patients [12]; i.e. for most patients referral will
exclude cancer. One significant concern is patients not being seen by a
specialist within two weeks of referral, and receiving hospital trusts
may be penalised for breach of two-week target, classified as fewer than
93% of referred patients being seen within two weeks [13]. One
common reason for breach is appointment postponement or non-at-
tendance by the patient. This has been reported anecdotally as being
problematic in several trusts but not previously researched. While
cancer waiting times data indicate that the 93% standard is met na-
tionally [11], these data do not take account of patients never seen as
part of their 2WW referral.
Social and demographic patterning of patient non-attendance has
been found in other health settings [14–16], with a focus on wasted
resources and service costs, and has also been noted in cancer screening
uptake [17–19]. In the 2WW setting, in which symptomatic patients are
being referred by GPs to specialist services, concerns about non-atten-
dance are not only about resource waste but also the potential for de-
layed diagnosis and treatment, and any impact on mortality. In this
study there was an opportunity to analyse a data set at a large regional
cancer centre in one NHS hospital Trust over seven years, to dis-
aggregate non-attendance (including cancellation and did not attends)
at urgent referral appointments for suspected cancer, to identify pa-
tient-level and practice-level predictors of non-attendance, and analyse
patient outcomes including cancer diagnosis and mortality rates.
2. Method
2.1. Study setting and population
A cohort study was conducted based on routinely collected health-
care records from a single NHS hospital, The Leeds Teaching Hospitals
Trust (LTHT), which provides comprehensive cancer services for a po-
pulation of over 750,000 [20]. Information was derived from the LTHT
electronic health record ‘Patient Pathway Manager’ (PPM) which in-
tegrates clinically relevant data (patient, appointment, diagnostic in-
formation, etc.) on all patients within the Trust including those referred
or reviewed with a suspected cancer diagnosis [21]. The PPM database
is used for generating mandatory reports for Cancer Waiting Times; for
this study, data linkage to other Trust systems was also utilised to
provide additional data. Over the study period healthcare in this pre-
dominantly urban area was organised at a population level across three
Clinical Commissioning Groups (CCGs), jointly including 105 general
practices.
In England and Wales, the 2WW pathway is operationalised via
suspected cancer site, with the patient’s GP determining which specialty
to refer to, based on the signs and symptoms at presentation. Suspected
cancer site specific referral forms are completed by the GP and received
by the hospital Trust within 24 h (ideally), at which point suitable pa-
tients are accepted onto the 2WW pathway and the referral period
begins. This referral period can normally be terminated in one of two
ways: i) the patient is seen by the Trust or, ii) the Trust refers the pa-
tient back to the GP.
2.2. Study sample
The study sample comprised all adults currently registered with a
general practice within the three Leeds CCGs, referred to LTHT between
1st April 2009 and 31st December 2016 on the ‘urgent referral pathway
for suspected cancer’ (2WW) pathway for the following cancer sites:
head and neck; upper gastrointestinal (GI); lower GI; hepato-pancreato-
bilary (HPB); lung; skin; sarcoma; breast; gynaecology; urology; testi-
cular; brain/central nervous system (CNS); thyroid; haematology. There
were only small numbers of referrals for suspected haematological,
brain/CNS, sarcoma and paediatric cancers; for analysis these cancer
sites were combined into an ‘other’ category, alongside any referrals
recorded by LTHT as ‘other’. In the study area the pathway for the
overwhelming majority of suspected lung cancer patients is via com-
munity-ordered chest X-ray and not through the 2WW pathway; it is not
possible to distinguish the chest X-ray referrals in PPM. A small pro-
portion of lung cancer referrals were recorded as 2WW, as a con-
sequence either of referral without chest X-ray or a parallel referral and
these were also categorised as ‘other’. In accordance with Trust re-
cording systems and relevant NICE guidelines [10], referrals with sus-
pected HPB were included in upper GI and suspected thyroid cancer
referrals were included with head and neck for analysis. Patients re-
ferred on the 2WW pathway are offered either an outpatient appoint-
ment or, if suitable, a straight-to-test (STT) appointment such as colo-
noscopy.
Patients were followed up for vital status until 5th July 2018 via
PPM data extract on this date; cancer stage, where relevant and avail-
able, was identified by linkage to the National Cancer Registration and
Analysis Service (NCRAS). Patients can be referred to the 2WW
pathway more than once. Where multiple referrals were recorded, only
the first referral period in the study window was taken as the index
referral and formed the basis for analysis. Only patients with complete
information on patient and general practice variables of interest were
included in analysis (missing data were not imputed; see Fig. 1).
2.3. Individual and organisational variables
Patient demographics (age at index referral, sex); referral pathway
characteristics (referral date, suspected cancer site, appointment type
(outpatient or STT, where available), attendance date, and diagnostic
outcomes (recorded referral outcome; recorded cancer diagnosis and
date of diagnosis) were taken directly from PPM. We were unable to
include patient ethnicity as a variable, given poor levels of recording
and concerns about accuracy. An area-based measure of socio-economic
deprivation (income domain of Index of Multiple Deprivation (IMD)
2015 at lower super output area, covering approximately 1500 people)
[22] and straight-line distance to the hospital were derived from the
patient’s current recorded home postcode. In Leeds patients referred
urgently for suspected cancer are seen at one of five LTHT hospitals,
based on four sites throughout the city, depending on the suspected
cancer site. Distance was therefore measured from the postcode cen-
troid [23] to the hospital associated with the cancer site. Where pa-
tients could be seen at one of several hospitals (e.g. patients with sus-
pected lower GI cancer), the hospital where the cancer centre is located
and where the majority of referred patients are seen was used for
analysis.
Only details of patients’ current general practice were retained on
hospital records and this was used to assign ‘practice-level’ character-
istics; it was not possible to determine patients’ general practice at re-
ferral or whether this had changed. The practice-level data included in
the analysis were: 2015 list size [24]; 2015-16 UK Quality and Out-
comes Framework (QOF) overall population achievement scores [25];
2015-16 GP patient satisfaction survey overall domain scores [26];
average 2WW conversion rates between 2009 and 2016 (the proportion
of 2WW referrals resulting in a diagnosis of cancer); and average 2WW
detection rates between 2009 and 2016 (the proportion of cancer di-
agnoses identified via 2WW) [12]. We included both the conversion
and detection rates of practices as a high conversion rate alone may not
necessarily be a positive indicator; the two rates are important practice
indicators when considered in tandem [27]. Practice-level deprivation
was calculated using the income domain of the IMD (2015) averaging
all practice-registered patients (not just the study sample).
2.4. Waiting list process and clinical outcomes
The outpatient appointment attendance date was taken from PPM
along with recorded reasons for non-attendance (‘cancelled by patient’;
‘did not attend’; ‘cancelled by the Trust’, ‘unknown’). In PPM ‘cancelled
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by patient’, in combination with other data, can also be used to identify
postponements; such patients will have both a ‘cancelled by patient’
appointment and a subsequent ‘attended’ appointment. In PPM patients
with STT appointments can only be identified if they attended; non-
attendance will generally result in the appointment type being ‘un-
known’, however this is not exclusive to STT. When no information was
available to distinguish the appointment type it was set to ‘unknown’.
For the ‘unknown’ appointment type free text was sometimes available,
enabling categorisation of reasons for non-attendances (by RS, then
cross-checked by SEO). For all appointment types, PPM records also
identified if a patient had been admitted to hospital acutely prior to
their appointment or if they had opted for a private healthcare pro-
vider.
Clinical outcomes included a classification of the 2WW referral
outcome as recorded in PPM (e.g. ‘on cancer pathway’, ‘on non-cancer
pathway’). Data linkage within PPM also provided data on the first
diagnosis of cancer in the six months following the conclusion of the
index referral period. This allowed us to capture diagnoses which were
not made at the referral (e.g. patients ‘on non-cancer pathway’), but
which were made within a timeframe such that the symptoms which led
to referral may have been relevant to the diagnosis. For patients whose
referral outcome was ‘on cancer pathway’, this diagnostic data would
be the same as that identified via data linkage. ICD10 codes were used
to identify cancer diagnoses. Diagnoses of basal cell carcinoma sub-
sequent to 2WW referral were identified using text string searches and
were not categorised as a cancer diagnosis for analysis. Data on cancer
stage at diagnosis were available for only a small subset of those pa-
tients diagnosed between 2009 and 2013.
2.5. Statistical analysis
2.5.1. Clinic attendance
The primary outcome for analysis was ‘non-attendance’ vs. ‘any at-
tendance’. ‘Non-attendance’ included patients not seen at any ap-
pointment during their index 2WW referral period; ‘attendance’ in-
cluded those seen at any point during this period, even if they were seen
beyond the two week target. Associations between individual and
‘practice-level’ factors were explored using multilevel logistic regres-
sion, with patients’ current practice as the higher level term. Individual
characteristics included were: age at referral (18–29, 30–65, 66–84,
85+ years); sex; area-based measure of deprivation (lower super output
area on basis of national quintiles: 1=least deprived; 5=most de-
prived); referral year; straight-line distance to hospital; and suspected
cancer site (head and neck, lower GI, upper GI, skin, breast, gynaeco-
logical, urological, and ‘other’). Practice-level factors included were: list
size (study area-specific quintiles, 1=smallest; 5=largest); general
practice deprivation (study area-specific national quintiles, 1=least
deprived; 5=most deprived); QOF score (higher score indicating better
performance); GP patient satisfaction score (proportion of patients
rating the practice as ‘good’); practice 2WW conversion rate (proportion
of 2WW referrals resulting in cancer diagnosis) and practice 2WW de-
tection rate (proportion of cancers diagnosed in patients at the practice
via 2WW). Continuous practice level factors were normalised using z-
scores prior to analysis. Whole data set analysis was conducted with
subgroup analysis for suspected cancer site; referral year was added as
an interaction term.
2.5.2. Diagnostic and early mortality outcomes
The diagnostic outcome was the first cancer diagnosed (excluding
basal cell carcinoma) within six months of the index referral period
concluding; diagnoses were included regardless of whether the cancer
site matched the cancer suspected at referral. Six months was con-
sidered by clinical experts to be a reasonable threshold for cancers to be
causally linked with the symptoms that triggered referral. One year
overall mortality was calculated from the date of cancer diagnosis.
Associations between initial 2WW clinic attendance (attended vs
non-attended) and diagnostic and mortality outcomes were examined
using Cox’s proportional hazard regression models, including individual
terms for the suspected cancer site (where relevant), type of cancer
diagnosed and those individual factors associated with attendance.
All variables discussed in the text and tables were included in the
models simultaneously. Variable selection was consequent and
Fig. 1. Flow diagram showing identification of patients in the final sample (percent of full sample).
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constrained on availability within a routine data source and informed
by the research literature. Exact p-values are reported throughout and
all analyses were carried out in SPSS (version 24).
2.5.3. Patient involvement
One patient was involved in the development of the research grant
application and protocol. A Patient and Public Involvement Advisory
Group (four members) met regularly throughout the study and offered
advice on study plans and progress. The study results will not be dis-
seminated to individual study participants due to the anonymised da-
taset.
3. Results
3.1. Characteristics of the sample
Data were extracted for 157,974 referrals to the Trust between April
2009 and December 2016; 36,803 of these were a subsequent referral
and not the index referral, and so were removed from analyses. After
data cleaning and the removal of non-index referral periods 109,433
patients registered at 105 general practices in Leeds were included in
the final sample (Fig. 1).
The characteristics of participants and their current registered
general practices are provided in Table 1. The mean age of included
patients was 56.7 years (SD=18.3) and the majority of referred pa-
tients were women (67,984, 62.1%), largely due to the high volume of
referrals for suspected breast and gynaecological cancers. One quarter
of referred patients lived in areas of high deprivation (27,994, 25.6%),
but the proportions varied by suspected cancer site. For example, 26.8%
patients (6561) referred with suspected skin cancer were in the least
deprived quintile nationally. The number of referrals to LTHT increased
each year over the study period. Most referrals led to outpatient ap-
pointments (77,075, 70.4%), but STT attendances were also common,
particularly for suspected lower (9,447, 54.7%) and upper (7,055,
74.1%) gastrointestinal cancers. There was little patterning of referrals
according to practice characteristics.
3.2. Factors associated with non-attendance
A total of 5673 (5.2%) patients did not attend their index 2WW
referral (non-attended), of whom 3893 (68.6%) were scheduled to have
an outpatient appointment. Outpatient non-attendance was largely due
to cancellation (40.6%), did not attend (DNA) (31.4%) or a combina-
tion of the two (14.9%). An additional small proportion of patients
(1,267, 1.2% of total sample) were not seen due to: provider cancel-
lations; opting for private healthcare; being seen in another hospital
Trust; admission to hospital, or dying prior to appointment. These pa-
tients were removed from all further analyses (Fig. 1).
Patients aged 18–29 and those aged over 85 years had the highest
proportion of non-attendance at their index 2WW referral, 7.9% and
7.7% respectively (Table 2). Men were more likely to non-attend than
women (5.8% versus 4.9%), and non-attendance was highest in the
most deprived quintile (6.6%) and lowest in the least deprived quintile
(4.4%). Non-attendance reduced over the study period (5.8% in
2009–2010; 4.9% in 2015–2016). Non-attendance also varied by the
suspected cancer site; the highest proportions were seen in referral with
suspected upper gastrointestinal cancer (8.1%) and lowest in those with
suspected breast cancer (3.7%). A significant interaction was observed
between referral year and suspected cancer site; non-attendance re-
duced over time for those referred on the following suspected cancer
sites: head and neck (OR 0.95, p=0.013, 95% CI= 0.91 to 0.99), skin
(OR 0.93, p < 0.001, 95% CI= 0.89 to 0.96), gynaecological (OR
0.93, p= 0.007, 95% CI=0.88 to 0.98), and urological (OR 0.95,
p=0.022, 95% CI= 0.90 to 0.99). Non-attendance increased with
referral year for those categorised as ‘other’ for the suspected cancer site
(OR 1.08, p=0.021, 95% CI=1.01–1.15). There was a small but
statistically significant effect of distance to hospital on attendance;
those who did not attend lived further away (mean =8.1 km) than
those who attended (mean =7.7 km).
Regarding general practice characteristics, there was a trend for
patients currently registered at general practices in the most deprived
quintile to be most likely to non-attend (6.3%) compared to those in the
least deprived quintile (4.7%) (Table 2). In the unadjusted model pa-
tients from general practices with higher QOF scores, higher 2WW
conversion rates and higher 2WW detection rates were less likely to
non-attend. These factors were largely attenuated in the adjusted
model, with the exception of the association between 2WW detection
rate and non-attendance.
We also examined patients classified as having breached the two-
week target, either due to non-attendance or having attended after two
weeks. A total of 13,446 (12.4%) patients were categorised as having
breached for their index 2WW referral. Using this outcome variable
rather than attendance versus non-attendance, did not modify the
pattern of findings and therefore the results are not reported.
3.3. Non-attendance by suspected cancer site
The pattern of results observed in the whole dataset analysis re-
mained when analysis was stratified by suspected cancer site; patients
who did not attend their index 2WW referral were more likely in the
youngest (18–29 years) or oldest (85+ years) age groups, males, living
in an area of higher deprivation, and referred on the 2WW pathway
earlier in the data collection period. Analyses are reported in
Supplementary Table 1.
3.4. Outcomes following referral
3.4.1. Diagnosis of cancer
A total of 10,360 (9.6%) patients were diagnosed with cancer within
six months of index 2WW referral (92.1% of these were diagnosed
within three months). Of those 8644 (83.4%) were diagnosed with a
cancer which matched the suspected cancer at referral, although this
varied by cancer site: head and neck, 61.2%; upper gastrointestinal,
62.8%; lower gastrointestinal, 70.7%; skin, 92.5%; breast, 96.4%; gy-
naecological, 84.0%; urological, 91.9%; and ‘other’, 87.1%.
The rate of cancer diagnosis was higher among patients who at-
tended their index 2WW referral (9.8%) than among non-attenders
(5.6%) (Table 3). There was a small but statistically significant differ-
ence in the median time to diagnosis; 22 days (interquartile range
12–44 days) for attending patients and 34 days (interquartile range
14–70 days) for non-attending patients (p < 0.001). Other patient
factors influencing the risk of cancer diagnosis included age, sex, re-
ferral year and suspected cancer site. Patients aged 85 years or older
had the greatest risk of cancer diagnosis (19.5%) and those aged 18–29
years had the lowest risk (1.5%). Men were more likely to be diagnosed
with cancer (13.3%) than women (7.3%), and the risk of diagnosis
decreased with referral year (12.4% in 2009–2010 to 7.6% in
2015–2016). Finally, the proportion of patients diagnosed with cancer
was greatest for those with ‘other’ suspected cancers (23.0%) and
smallest for those with suspected skin cancer (5.8%). Patient depriva-
tion did not influence risk of cancer diagnosis in the adjusted model,
and only a small effect was observed in the unadjusted model.
Among the diagnosed patients who attended an appointment during
their index referral period, 9100 (90.9%) of patients were placed on the
‘cancer pathway’ at the conclusion of the referral period, i.e. they were
diagnosed at referral. The remaining 916 (9.1%) attending patients
were placed on the ‘non-cancer pathway’ but were diagnosed within six
months of referral; 309 (33.7%) of these patients had another 2WW
referral prior to their diagnosis. The other 607 (66.3%) attending pa-
tients were diagnosed presumably through another route, e.g. emer-
gency presentation. Among diagnosed patients not attending during
their index 2WW referral period (n= 316), 128 (40.4%) had another
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Table 1
Patient and practice characteristics of the sample by suspected cancer site.
All suspected
cancer n= 109433
Head & neck
(suspected)
n=13666
Upper GI
(suspected)
n=9524
Lower GI
(suspected)
n=17278
Skin (suspected)
n= 24493
Breast (suspected)
n= 18528
Gynaecological
(suspected) n= 8880
Urological
(suspected)
n=11868
Other (including
Lung)a(suspected) n= 5196
Patient characteristics
Age (mean [SD]) 56.7 [18.3] 54.5 [17.4] 64.5 [14.6] 66.6 [13.4] 53.7 [20.6] 45.8 [16.3] 53.8 [15.6] 62.8 [15.9] 59.8 [18.3]
Sex (n [%])
Male 41449 [37.9] 5947 [43.5] 4422 [46.4] 7983 [46.2] 10,413 [42.5] 987 [5.3] – 8985 [75.7] 2712 [52.2]
Female 67984 [62.1] 7719 [56.5] 5102 [53.6] 9295 [53.8] 14,080 [57.5] 17,541 [94.7] 8880 [100] 2883 [24.3] 2484 [47.8]
Deprivation (n [%])
Least deprived 23,916 [21.9] 2595 [19.0] 1657 [17.4] 3546 [20.5] 6561 [26.8] 3935 [21.2] 1922 [21.6] 2748 [23.2] 952 [18.3]
Second quintile 24,955 [22.8] 2814 [20.6] 2022 [21.2] 3970 [23.0] 6166 [25.2] 4084 [22.0] 2059 [23.2] 2798 [23.6] 1042 [20.1]
Third quintile 15,507 [14.2] 1901 [13.9] 1319 [13.8] 2385 [13.8] 3520 [14.4] 2682 [14.5] 1341 [15.1] 1672 [14.1] 687 [13.2]
Fourth quintile 17,061 [15.6] 2224 [16.3] 1559 [16.4] 2767 [16.0] 3582 [14.6] 2923 [15.8] 1296 [14.6] 1843 [15.5] 867 [16.7]
Most deprived 27994 [25.6] 4132 [30.2] 2967 [31.2] 4610 [26.7] 4664 [19.0] 4904 [26.5] 2262 [25.5] 2807 [23.7] 1648 [31.7]
Referral Year (n [%])
2009-10b 19865 [18.2] 2361 [17.3] 1451 [15.2] 2886 [16.7] 4315 [17.6] 3998 [21.6] 1642 [18.5] 1996 [16.8] 1216 [23.4]
2011-12 25111 [23.0] 3160 [23.1] 2170 [22.8] 4082 [23.6] 5473 [22.4] 4140 [22.3] 1946 [21.9] 2683 [22.6] 1457 [28.0]
2013-14 30097 [27.5] 3781 [27.7] 2601 [27.3] 4907 [28.4] 6782 [27.7] 4846 [26.2] 2373 [26.7] 3554 [30.0] 1253 [24.1]
2015-16 34360 [31.4] 4364 [31.9] 3302 [34.7] 5403 [31.3] 7923 [32.4] 5544 [29.9] 2919 [32.9] 3635 [30.6] 1270 [24.4]
Distance home to hospital
(km) mean [SD]
7.2 [12.9] 7.1 [12.4] 7.3 [11.1] 7.7 [12.6] 8.1 [15.0] 7.8 [12.6] 7.7 [10.1] 7.8 [13.2] 7.6 [14.4]
Appointment Type (n [%])
Straight-to-test 29,325 [26.8] 0 [0.0] 7055 [74.1] 9447 [54.7] 0 [0.0] 0 [0.0] 0 [0.0] 9447 [54.7] 2810 [54.1]
Outpatient 77075 [70.4] 13,551 [99.2] 1434 [15.1] 6927 [40.1] 24,284 [99.1] 18,400 [99.3] 8787 [99.0] 6927 [40.1] 2072 [39.9]
Unknown 3033 [2.8] 115 [0.8] 1035 [10.9] 904 [5.2] 209 [0.9] 128 [0.7] 93 [1.0] 904 [5.2] 314 [6.0]
Practice characteristics
Practice deprivation (n
[%])
First quintile - least deprived 20,926 [19.1] 2079 [15.2] 1681 [17.7] 3495 [20.2] 4928 [20.1] 3548 [19.1] 1785 [20.1] 2523 [21.3] 887 [17.1]
Second quintile 22,798 [20.8] 2682 [19.6] 1615 [17.0.] 3615 [20.9] 5751 [23.5] 3850 [20.8] 1825 [20.6] 2421 [20.4] 1039 [20.0]
Third quintile 22,068 [20.2] 2728 [20.0] 1835 [19.3] 3175 [18.4] 5317 [21.7] 3843 [20.7] 1755 [19.7] 2418 [20.4] 997 [19.2]
Fourth quintile 21,978 [20.1] 3045 [22.3] 2041 [21.4] 3290 [19.0] 4723 [19.3] 3741 [20.2] 1764 [19.8] 2233 [18.8] 1141 [22.0]
Fifth Quintile - most deprived 21,663 [19.8] 3132 [22.9] 2352 [24.7] 3703 [21.4] 3774 [15.4] 3546 [19.1] 1751 [19.8] 2273 [19.2] 1132 [21.8]
List size quintiles (n [%])
Smallest (1515 to 6191) 21,511 [19.7] 2738 [20.0] 2006 [21.1] 3345 [19.4] 4481 [18.3] 3604 [19.5] 1741 [20.1] 2475 [20.9] 1121 [21.6]
Second (6247 to 8835) 21,914 [20.0] 2710 [19.8] 1858 [19.5] 3549 [20.5] 5092 [20.8] 3670 [19.8] 1746 [19.7] 2297 [19.4] 992 [19.1]
Third (8956 to 12,829) 21,768 [19.9] 2564 [18.8] 1927 [20.2] 3298 [19.1] 5180 [21.1] 3488 [18.8] 1823 [20.5] 2479 [20.9] 1009 [19.4]
Fourth (12,861 to 15,086) 22,915 [20.9] 2924 [21.4] 1987 [20.9] 3885 [22.5] 4668 [19.1] 3980 [21.5] 1849 [20.5] 2549 [21.5] 1073 [20.7]
Largest (15,861 to 35,319) 21,325 [19.5] 2730 [20.0] 1746 [18.3] 3201 [18.5] 5072 [20.7] 3786 [20.4] 1721 [19.2] 2068 [17.4] 1001 [19.3]
QoFc percentage score
(mean [SD])
83.9 [3.1] 83.6 [3.4] 83.9 [2.8] 84.0 [2.7] 83.8 [3.5] 83.8 [3.0] 83.9 [2.9] 84.1 [2.8] 83.8 [3.2]
Patient satisfaction (mean
[SD])
86.6 [7.9] 86.3 [7.8] 86.2 [8.0] 86.6 [7.8] 87.1 [8.1] 86.5 [7.9] 86.6 [7.7] 86.5 [8.1] 86.5 [7.7]
Conversion rate (mean
[SD])
8.2 [2.0] 8.1 [2.0] 8.2 [1.9] 8.4 [1.9] 8.1 [2.1] 8.3 [2.0] 8.3 [1.9] 8.4 [1.9] 8.2 [2.0]
Detection rate (mean [SD]) 43.7 [5.2] 43.5 [5.3] 43.7 [5.2] 43.6 [5.2] 43.9 [5.2] 43.6 [5.0] 43.7 [5.2] 43.8 [5.1] 43.6 [5.2]
a ‘Other’ category includes lung cancer (n= 2732), haematological cancer (n= 1171), paediatric cancers (n= 4), sarcomas (n=369), brain/CNS cancer (n= 855) and other (n= 65).
b Incomplete year of data for 2009 (data included from April to December).
c QoF, Quality and Outcomes Framework.
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Table 2
Patient and practice factors associated with patient non-attendance at index 2WW referral (n= 108,166).
Factors Non-attended n=5673 [5.2%] Attended n=102,493 [94.8%] Unadjusted model Adjusted modela
Odds Ratio [95% CI] P diff Odds Ratio [95% CI] P diff
Patient factors
Age Group
18-29 years 783 [7.9] 9185 [92.1] 1.58 [1.45 to 1.72] < 0.001 1.76 [1.61 to 1.92] <0.001
30-64 years 2887 [5.0] 54,787 [95.0] (ref) (ref)
65-84 years 1583 [4.5] 33,417 [95.5] 0.92 [0.86 to 0.98] 0.80 [0.75 to 0.85]
85+ years 420 [7.6] 5104 [92.4] 1.60 [1.44 to 1.78] 1.41 [1.26 to 1.57]
Sex
Male 2369 [5.8] 38,522 [94.2] 1.19 [1.13 to 1.26] < 0.001 1.10 [1.03 to 1.17] 0.002
Female 3304 [4.9] 63,971 [95.1] (ref) (ref)
Deprivation
Least deprived 1047 [4.4] 22,566 [95.6] (ref) < 0.001 (ref) < 0.001
Second quintile 1108 [4.5] 23,579 [95.5] 1.02 [0.93 to 1.11] 1.01 [0.92 to 1.10]
Third quintile 752 [4.9] 14,576 [95.1] 1.12 [1.02 to 1.24] 1.10 [0.99 to 1.22]
Fourth quintile 953 [5.7] 15,912 [94.3] 1.27 [1.15 to 1.40] 1.24 [1.12 to 1.37]
Most deprived 1813 [6.6] 25,860 [93.4] 1.47 [1.35 to 1.61] 1.40 [1.28 to 1.54]
Referral year
2009-10 1141 [5.8] 18,559 [94.2]
2011-12 1393 [5.6] 23,507 [94.4]
2013-14 1487 [5.0] 28,221 [95.0]
2015-16 1652 [4.9] 32,206 [95.1]
Continuous – – 0.97 [0.96 to 0.98] < 0.001 0.96 [0.95 to 0.97] <0.001
Distance home to hospital (km) mean [SE] 8.1 [0.2] 7.7 [0.0] 1.00 [1.00 to 1.00] p trend 0.002 1.00 [1.00 to 1.00] p trend 0.001
Suspected cancer site
Head & neck 737 [5.4] 12,849 [94.6] 0.81 [0.74 to 0.90] < 0.001 0.74 [0.67 to 0.83] <0.001
Upper GI 747 [8.1] 8464 [91.9] 1.27 [1.16 to 1.40] 1.25 [1.12 to 1.40]
Lower GI 1094 [6.4] 15,935 [93.6] (ref) (ref)
Skin 1309 [5.4] 23,109 [94.6] 0.83 [0.76 to 0.90] 0.72 [0.65 to 0.80]
Breast 674 [3.7] 17,745 [96.3] 0.55 [0.50 to 0.60] 0.48 [0.42 to 0.54]
Gynaecological 333 [3.8] 8496 [96.2] 0.57 [0.50 to 0.65] 0.54 [0.47 to 0.63]
Urological 533 [4.5] 11,208 [95.5] 0.70 [0.62 to 0.77] 0.66 [0.58 to 0.74]
Other (including Lung)b 246 [5.0] 4687 [95.0] 0.75 [0.65 to 0.87] 0.67 [0.58 to 0.79]
Practice factors
Practice deprivation
Least deprived 978 [4.7] 19,586 [95.3] (ref) < 0.001 (ref) 0.058
Second quintile 982 [4.4] 21,435 [95.6] 0.90 [0.77 to 1.06] 0.81 [0.70 to 0.96]
Third quintile 1107 [5.1] 20,520 [94.9] 1.03 [0.88 to 1.21] 0.83 [0.69 to 0.98]
Fourth quintile 1266 [5.8] 20,388 [94.2] 1.19 [1.01 to 1.39] 0.91 [0.77 to 1.07]
Most deprived 1340 [6.3] 20,001 [93.7] 1.32 [1.13 to 1.53] 0.93 [0.78 to 1.11]
List size (quintiles)
Smallest (1515 to 6191) 1158 [5.4] 20,098 [94.6] (ref) 0.631 (ref) 0.868
Second (6247 to 8835) 1086 [5.0] 20,576 [95.0] 0.90 [0.78 to 1.05] 0.96 [0.83 to 1.10]
Third (8956 to 12,829) 1088 [5.1] 20,427 [94.9] 0.95 [0.81 to 1.12] 0.97 [0.84 to 1.12]
Fourth (12,861 to 15,086) 1280 [5.6] 21,385 [94.4] 1.03 [0.87 to 1.23] 0.99 [0.87 to 1.15]
Largest (15,861 to 35,319) 1061 [5.0] 20,007 [95.0] 0.96 [0.79 to 1.15] 1.04 [0.87 to 1.23]
QoFc percentage score (mean [SD]) 83.5 [3.4] 83.9 [3.1]
Per one SD change 0.89 [0.84 to 0.95] p trend < 0.001 0.98 [0.92 to 1.05] p trend 0.617
Patient satisfaction (mean [SD]) 86.3 [7.8] 86.6 [7.9]
Per one SD change 0.96 [0.90 to 1.02] p trend 0.182 1.03 [0.97 to 1.09] p trend 0.331
Conversion rate (proportion [SD]) 8.1 [2.0] 8.2 [2.0]
(continued on next page)
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2WW referral before diagnosis.
3.4.2. Early mortality
Among patients diagnosed with cancer within 6 months of referral,
2029 (19.6%) died within 12 months of diagnosis (Table 4). The risk of
dying within 12 months of diagnosis was greater for patients who did
not attend their index 2WW referral (31.3%) than for those who at-
tended (19.2%), although the rate varied by diagnosed cancer site. For
example, the proportion of patients with breast cancer who died within
12 months was 14.3% for patients who did not attend their appoint-
ment and 5.0% for those who attended; this effect was somewhat at-
tenuated in the adjusted model. Overall, there was a small difference in
the median time to death; 128 days (interquartile range 54–236 days)
for those who attended their index 2WW referral and 123 days (inter-
quartile range 46–233 days) for those who did not attend (p=0.480).
Data on cancer stage at diagnosis were available for a small pro-
portion of patients (1,693, 16.3%). Patients who were not seen at 2WW
had higher rates of advanced cancer (stage 4, 34.6%) compared to those
who were seen (18.4%), as did patients who died within one year of
cancer diagnosis (62.0% vs 12.2%). Stage at diagnosis also varied by
cancer site; patients with upper gastrointestinal or ‘other’ cancers had
the highest proportion of advanced cancer (46.8% and 50.9% respec-
tively) and patients with skin cancer had the lowest proportion (3.3%).
4. Discussion
Our analysis of urgent referrals for suspected cancer showed that
most patients attended and were seen by a specialist within the planned
two-week target, with both number of referrals and attendance rates
increasing year on year. However a minority of patients did not attend
their index 2WW referral; this was more likely among the youngest and
oldest patients, men, patients with certain suspected cancers, those
living in more deprived areas and those living further from the hospital.
Individual patient factors were more important predictors of non-at-
tendance than factors associated with practices; only practice 2WW
cancer detection rate influenced non-attendance after modelling ad-
justments. While non-attending patients had lower rates of cancer di-
agnosis, cancer outcomes were worse in non-attending patients. This
effect was sustained after adjustment for other predictors of mortality,
but it differed depending on the cancer type diagnosed.
The study was undertaken in a single NHS hospital Trust in Leeds, a
large-sized city, including inner-city, suburban and semi-rural housing,
a wide range of income levels and areas of the city with a multi-ethnic
population. The context of the city and Trust, and the introduction of
local initiatives to increase attendance, such as providing patients with
enhanced information about 2WW referrals and highlighting the clin-
ical concern for cancer, may reduce the generalisability to other set-
tings. Nevertheless, the 2WW referral pathway is governed by nation-
wide guidelines [10] and Leeds is a typical tertiary cancer care setting.
Leeds is nationally untypical in one respect: historically there has been
a different referral pathway for respiratory problems in Leeds, meaning
that relatively few patients with suspected lung cancer are referred on
the urgent referral pathway.
Data were drawn from a single Trust but equivalent national data
are not currently available and this study had access to a large, routi-
nely collected historical dataset, augmented to enable research into
cancer outcomes. Levels of missing data were low and data were well
characterised, but some assumptions were needed and the origin of the
data meant we had no control over data quality or completeness. For
example, the way that non-attendance was recorded did not enable us
to calculate separate rates or predictive analyses for patients referred
for straight-to-test appointments. Furthermore, we could not explore
the explanatory effects of ‘ethnicity’, a potentially important limitation
given its known relationship in the UK with healthcare utilisation [28].
The use of routinely collected data meant that we could not assess the
impact of such variables as patients’ use of English, culturalTa
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understandings of health and disease, relationship status, co-morbidity,
or continuity of GP care, all of which may influence patient reporting of
symptoms and their navigation of the health system [29–32]. Ongoing
developments within the PPM system mean that data such as these are
becoming more accessible. The Two Week Wait policy has been subject
to updated NICE guidance, which significantly increased numbers of GP
referrals over the seven-year period of data collection on this study and
produced changes in cancer detection and conversion rates, meaning
that statistical relationships were being calculated in shifting ground
and may have introduced measurement error.
The predictors of non-attendance (age, sex, area-level deprivation)
were consistent with other settings; [14–16] although practice-level
factors were not strongly associated with attendance in our analyses.
However it is possible that relationships could be attenuated by some
misclassification consequent on only current practice being identifiable
in the dataset. However we have been unable to trace any published
accounts of the proportion of UK patients who change their general
practice registration annually, or whether patient moves tend to be
towards or away from practices in more deprived areas. Other possible
explanations for non-attendance specific to this setting, such as death or
hospital admission in the period between GP and hospital appoint-
ments, or patients opting for private healthcare following GP appoint-
ment, affected a very small proportion. Studies investigating non-at-
tendance for colonoscopy and colposcopy following screening have also
observed age as a contributory factor, alongside procedure fear
[33–35]. While not measured in this study, fear may be related to the
high rates of non-attendance associated with certain suspected cancer
sites, notably upper gastrointestinal. The conversion rate observed in
this study (the proportion of patients diagnosed with cancer following
referral) is similar to national figures [12] but does suggest systemic
under-referral of patients, given that since 2015 2WW guidelines have
recommended a referral threshold of 3% (5% prior to 2015), i.e. the
positive predictive value for cancer [10].
Non-attendance in other clinical settings (i.e. primary care and
hospital out-patient clinics) has been shown to be more common in
patients living in more deprived areas, which tend to have poorer
health outcomes [16] [31]. However, the relationship we observed of
higher one-year mortality amongst patients diagnosed with cancer who
were initially non-attenders following urgent referral is a novel finding
and important. Death within 12 months of cancer diagnosis is strongly
linked to advanced stage disease at diagnosis [7], and where staging
data were available they confirmed that more advanced cases were
present amongst initial non-attenders. There are a number of possible
explanations why initial non-attendance could be related to advanced
stage at diagnosis. A direct relationship between attendance behaviour
and stage as a consequence of a long interval between referral and di-
agnosis is possible [36–38], but the delays identified were generally
short (although highly variable) and seem unlikely to be sufficient to
account for significant disease progression. The presence of advanced
disease might contribute to initial non-attendance, as a consequence of
symptomatic disease or heightened anxiety. Finally, clinic non-atten-
dance may be acting as a marker for unmeasured patient characteristics
and health behaviours that have cumulatively allowed disease pro-
gression to an advanced stage at the time of presentation. An alternate
Table 3
Association of attendance and patient factors with diagnosis of cancer within six months.
Diagnosis of cancer n= 10,360 [9.6%] Unadjusted Adjusteda
Hazard Ratio [95% CI] p diff Hazard Ratio [95% CI] p diff
Attendance at index 2WW
Non-attended 316 [5.6] 0.56 [0.50 to 0.62] < 0.001 0.59 [0.53 to 0.66] <0.001
Attended 10,044 [9.8] (ref) (ref)
Age
18-29 years 153 [1.5] 0.24 [0.20 to 0.28] < 0.001 0.25 [0.22 to 0.30] <0.001
30-65 years 3647 [6.3] (ref) (ref)
65-84 years 5484 [15.7] 2.60 [2.49 to 2.71] 2.56 [2.45 to 2.67]
85+ years 1076 [19.5] 3.35 [3.13 to 3.60] 3.60 [3.35 to 3.85]
Sex
Male 5452 [13.3] 1.88 [1.81 to 1.96] < 0.001 1.62 [1.54 to 1.69] <0.001
Female 4908 [7.3] (ref) (ref)
Deprivation
Least deprived 2283 [9.7] (ref) (ref)
Second quintile 2434 [9.9] 1.02 [0.96 to 1.08] 0.027 0.99 [0.93 to 1.05] 0.897
Third quintile 1503 [9.8] 1.01 [0.95 to 1.08] 1.01 [0.94 to 1.08]
Fourth quintile 1620 [9.6] 0.99 [0.93 to 1.06] 1.01 [0.95 to 1.08]
Most deprived 2520 [9.1] 0.94 [0.89 to 0.99] 0.99 [0.93 to 1.04]
Referral Year
2009-10 2452 [12.4]
2011-12 2718 [10.9]
2013-14 2601 [8.8]
2015-16 2589 [7.6]
Continuous 0.84 [0.82 to 0.85] < 0.001 0.87 [0.85 to 0.88] <0.001
Distance home to hospital (km) mean [SE]
Diagnosed/not diagnosed 7.7 [0.1] / 7.7 [0.0] 1.00 [1.00 to 1.00] 0.810 1.00 [0.99 to 1.00] 0.361
Suspected cancer site
Head and Neck 963 [7.1] 0.86 [0.79 to 0.94] < 0.001 1.84 [1.09 to 1.29] <0.001
Upper GI 882 [9.6] 1.19 [1.09 to 1.29] 1.29 [1.18 to 1.40]
Lower GI 1402 [8.2] (ref) (ref)
Skin 1426 [5.8] 0.71 [0.66 to 0.76] 0.94 [0.88 to 1.02]
Breast 1533 [8.3] 1.04 [0.97 to 1.12] 2.25 [2.08 to 2.44]
Gynaecological 636 [7.2] 0.88 [0.80 to 0.97] 1.65 [1.50 to 1.82]
Urological 2391 [20.4] 2.70 [2.53 to 2.88] 2.62 [2.45 to 2.80]
Other (including Lung)b 1127 [23.0] 3.00 [2.77 to 3.24] 3.30 [3.05 to 3.57]
a Adjusted for age, sex, deprivation, referral year, distance to the hospital and suspected cancer site.
b ‘Other’ category includes lung cancer (n= 740), haematological cancer (n= 307), paediatric cancers (n= 0), sarcomas (n=59), brain/CNS cancer (n= 18),
and other cancers (n=3).
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Table 4
Patient characteristics by cancer type diagnosed within six months of referral and hazard ratio (HR) and confidence intervals (CI) predicting early mortality.
All cancers
n= 10,360
Head and neck
n= 624
Upper GI
n= 710
Lower GI
n= 1126
Skin n= 1384 Breast n= 1562 Gynaecological n= 607 Urological
n= 2456
Other (including
Lung)an=1891
Age (mean [SD]) 67.7 [14.4] 59.1 [13.7] 70.7 [11.0] 71.6 [11.2] 68.6 [17.7] 62.8 [16.7] 65.2 [13.3] 68.8 [12.6] 69.6 [13.0]
Sex (n [% male])
Male/Female 5452/4908 [52.6] 367/257 [58.8] 452/258 [63.7] 651/475 [57.8] 766/618 [55.3] 14/1548 [0.9] 0/607 [0.0] 2181/275 [88.8] 1021/870 [54.0]
Deprivation (n [%])
Least deprived 3812 [36.8] 168 [26.9] 217 [30.6] 426 [37.8] 627 [45.3] 574 [36.7] 223 [36.7] 977 [39.8] 600 [31.7]
Second quintile 2796 [27.0] 161 [25.8] 212 [29.9] 316 [28.1] 356 [25.7] 429 [27.5] 170 [28.0] 653 [26.6] 499 [26.4]
Most deprived 3752 [36.2] 295 [47.3] 281 [39.6] 384 [34.1] 401 [29.0] 559 [35.8] 214 [35.3] 826 [33.6] 792 [41.9]
Referral Year (n [%])
2009-10 2452 [23.7] 134 [21.5] 148 [20.8] 246 [21.8] 297 [21.5] 397 [25.4] 130 [21.4] 588 [23.9] 512 [27.1]
2011-12 2718 [26.2] 156 [25.0] 215 [30.3] 265 [23.5] 342 [24.7] 394 [25.2] 165 [27.2] 627 [25.5] 554 [29.3]
2013-14 2601 [25.1] 144 [23.1] 187 [26.3] 283 [25.1] 351 [25.4] 408 [26.1] 171 [28.2] 619 [25.2] 438 [23.2]
2015-16 2589 [25.0] 190 [30.4] 160 [22.5] 332 [29.5] 394 [28.5] 363 [23.2] 141 [23.2] 622 [25.3] 387 [20.5]
Distance home to hospital (km) mean
[SE]
7.7 [0.1] 7.1 [0.6] 7.1 [0.4] 7.8 [0.3] 8.5 [0.5] 7.7 [0.4] 7.4 [0.5] 7.8 [0.3] 7.6 [0.3]
Time to diagnosis (n [% diagnosed
within one month])
Within one month/After one month 6255/4105 [60.4] 329/295 [52.7] 487/223 [68.6] 448/678 [39.8] 742/642 [53.6] 1390/172 [89.0] 319/288 [52.6] 1654/802 [67.3] 886/1005 [46.9]
Attendance at index 2WW referral (n
[% non-attended])
Non-attended/attended 316/10,044 [3.1] 19/588 [3.1] 34/676 [4.8] 37/1089 [3.3] 37/1347 [2.7] 28/1534 [1.8] 19/588 [3.1] 66/2390 [2.7] 76/1815 [4.0]
Mortality (n [%])
Attended 1930 [19.2] 93 [15.4] 402 [59.5] 208 [19.1] 81 [6.0] 76 [5.0] 64 [10.9] 235 [9.8] 771 [42.5]
Non-attended 99 [31.3] 5 [26.3] 22 [64.7] 13 [35.1] 2 [5.4] 4 [14.3] 4 [21.1] 8 [12.1] 41 [53.9]
HR [95% CI]
Unadjusted
1.76 [1.44 to 2.15] 1.77 [0.72 to
4.35]
1.20 [0.78 to
1.84]
2.01 [1.15 to
3.52]
0.89 [0.22 to
3.60]
3.18 [1.16 to
8.69]
2.04 [0.74 to 5.61] 1.25 [0.62 to 2.53] 1.36 [0.99 to 1.86]
HR [95% CI]
Adjustedb
1.76 [1.44 to 2.16] 3.14 [1.23 to
8.02]
1.34 [0.86 to
2.07]
1.81 [1.03 to
3.19]
0.90 [0.22 to
3.67]
2.69 [0.95 to
7.63]
2.43 [0.87 to 6.79] 1.17 [0.57 to 2.37] 1.38 [1.00 to 1.88]
a ‘Other’ category includes lung cancer (n= 950), haematological cancer (n=646), paediatric cancers (n=0), sarcomas (n= 125), brain/CNS cancer (n=21), and other cancers (n= 149).
b Adjusted for age group, sex, deprivation, referral year, distance to the hospital and time to diagnosis.
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explanation is that initial non-attendance is linked to factors that pre-
dispose to early disease progression and mortality regardless of initial
stage, for example, non-compliance with therapy, frailty or co-mor-
bidities. A linked qualitative study explores some of these possible ex-
planations, and addresses the potential for improvement through
changes within primary care and cancer services [39].
The study findings are important, with implications for primary care
and cancer services. They show that the urgent referral process results
in most patients being seen quickly by a specialist as intended, but that
is not the case for more than five percent of patients. Further, there are
worse health outcomes for those in the initial non-attending group who
are diagnosed with cancer. A new standard to ensure all patients are
informed whether they have cancer or not within 28 days is soon to be
introduced [40], although it is unclear if this change will impact on
patient non-attendance. The development of effective interventions
both to ensure greater proportions of patients present to the GP with
earlier stage disease and attend referral appointments, will depend on a
clearer understanding of the phenomenon [39]. The reported associa-
tion between patient deprivation and higher rates of diagnosis and early
mortality is consistent with other cancer settings [6,8,41,42]. However,
it is unclear the extent to which the effect reported here is mediated
through increased rates of multi-morbidity, lower health literacy, or
other factors. Replication, further investigation and clarification in
other trust settings, and the identification of candidate interventions,
are all warranted.
Supplementary information is available at the journal’s website.
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